ClinicalTrials.gg
CompletedNCT00335985Updated Nov 5, 2014

Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)

A Phase 3 interventional study of GB-0998 and Placebo of GB-0998 in Polymyositis and Dermatomyositis, sponsored by Japan Blood Products Organization. Completed at 1 site in Japan. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-11-05.

Primary conditionDermatomyositisRegistry: PolymyositisReclassifiedWhy we changed it
Registry
Polymyositis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dermatomyositis
Why
  1. The study's listed conditions name Dermatomyositis, a narrower term within Polymyositis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Japan Blood Products Organization · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies in Dermatomyositis with a site in Japan — 7 open to participants now, 8 under way, 4 of them phase 3. Dermatomyositis · Japan.

Enrollment
14th of 17
26 · median 144
Started
2006
the only one that year
Phase 3
9 of 18
4 open now
Registered
1st of 18
by date

Among the 18 studies in Dermatomyositis with a site in Japan, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2006, is one of 9 in phase 3, and was the 1st registered.

Dermatomyositis

184 studies on the registry are indexed under Dermatomyositis; 62 are open to participants now.

Browse Dermatomyositis studies →

Open to participants now

7 of the 18 studies in Dermatomyositis with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 49 Dermatomyositis studies recruiting now, 24 (49%) set no upper age limit and 15 (31%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Dermatomyositis with a site in Japan, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled trial will carry out to assess the efficacy of GB-0998 in the treatment of the steroid-resistant polymyositis and dermatomyositis based on the changes in manual muscle strength (MMT) scores as primary endpoint, and in addition, to assess the safety of GB-0998.

03

Conditions studied

  • Polymyositis
  • Dermatomyositis

Browse trials for

Keywords

  • polymyositis, dermatomyositis
  • High-dose intravenous immunoglobulin
  • Venoglobulin-IH
  • Steroid-resistant polymyositis(PM) and dermatomyositis(DM)
04

In context

Dermatomyositis Reclassified

184 studies on the registry are indexed under Dermatomyositis; 62 are open to participants now.

This study's enrollment of 26 is below the median of 35 across 130 interventional studies indexed under Dermatomyositis.

Browse Dermatomyositis studies →

Lead sponsor

Japan Blood Products Organization is the lead sponsor of 4 studies on the registry; none are open to participants now.

Compared within Dermatomyositis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Polymyositis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have been defined as "definite" based on the criteria of Bohan and Peter for polymyositis and dermatomyositis.
  • Patients who are defined as -resistant ones based on the changes of scores on manual muscle testing (MMT) and serum levels of creatine kinase (CK) during observation period before administration of drug.

Exclusion criteria

Exclusion Criteria:

  • Patients with malignant tumors.
  • Patients with acute interstitial pneumonia, including acute exacerbation of chronic.
  • Patients with severe muscular atrophy for a long period.
  • Patients with severe infectious disease.
  • Patients who have the anamnesis of shock or to this drug.
  • Patients with severe hepatic disorder or severe renal disorder.
  • Patients who have the anamnesis of cerebral infarction or ischemic heart disease, or who having symptom of these diseases.
  • Patients who have been diagnosed as IgA deficiency in their past history.
  • Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant.
  • Patients who were administered immunoglobulin dosage within 6 weeks before consent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    1

    Drug: GB-0998

  • Placebo comparator
    2

    Drug: Placebo of GB-0998

Interventions

  • 8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days

    Also known as: High-dose intravenous immunoglobulin, Venoglobulin-IH

  • DrugPlacebo of GB-0998

    8 mL/kg per day is intravenously administered for five successive days

07

What researchers measure

Primary outcomes

  1. Changes in manual muscle strength (MMT) scores

    Time frame: 8 weeks

Secondary outcomes

  1. Changes in the serum levels of creatine kinase (CK) and total scores of activities of daily living (ADL)

    Time frame: 8 weeks

  2. Adverse events and laboratory tests

    Time frame: 8 weeks

08

Study locations

1 site
  • Tokyo Medical and Dental University
    Bunkyo-ku, Tokyo 113-8519, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2006
First posted
Jun 12, 2006
Start
Jun 2006
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Last update
Nov 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00335985
Lead sponsor
Japan Blood Products Organization
Responsible party
Sponsor
First posted
Jun 12, 2006
Start date
Jun 2006
Primary completion
Mar 2009
Completion
Mar 2009
Last update
Nov 5, 2014

Study contacts

Nobuyuki Miyasaka, Professor
study chair · Tokyo Medical and Dental University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GB-0998

Start the discussion